The landscape of host genetic factors involved in immune response to common viral infections

Linda Kachuri^{1*}, Stephen S. Francis^{1,2,3,4*}, Maike Morrison^{5,6}, George A. Wendt², Yohan Bossé⁷, Taylor B. Cavazos⁸, Sara R. Rashkin^{1,9}, Elad Ziv^{3,10,11}, John S. Witte^{1,3,11,12}

* Authors contributed equally to this work

Affiliations:

- 1. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
- 2. Department of Neurological Surgery, University of California San Francisco, San Francisco, USA
- 3. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, USA
- 4. Weill Institute for Neurosciences, University of California San Francisco, San Francisco, USA
- 5. Summer Research Training Program, Graduate Division, University of California San Francisco, San Francisco, USA
- 6. Department of Mathematics, The University of Texas at Austin, Austin, USA
- 7. Institut universitaire de cardiologie et de pneumologie de Québec, Department of Molecular Medicine, Université Laval, Quebec City, Canada
- 8. Program in Biological and Medical Informatics, University of California San Francisco, San Francisco, USA
- 9. Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, USA
- 10. Department of Medicine, University of California, San Francisco, San Francisco, USA
- 11. Institute for Human Genetics, University of California San Francisco, San Francisco, USA
- 12. Department of Urology, University of California San Francisco, San Francisco, USA

Corresponding Authors:

Stephen S. Francis

Department of Neurological Surgery Helen Diller Family Comprehensive Cancer Center University of California, San Francisco 1450 3rd Street, Room 482, San Francisco, CA 94158 Email: stephen.francis@ucsf.edu

John S. Witte

Department of Epidemiology and Biostatistics Helen Diller Family Comprehensive Cancer Center University of California, San Francisco 1450 3rd Street, Room 388, San Francisco, CA 94158 Email: jwitte@ucsf.edu

1 ABSTRACT

Introduction: Humans and viruses have co-evolved for millennia resulting in a complex host genetic
 architecture. Understanding the genetic mechanisms of immune response to viral infection provides insight
 into disease etiology and therapeutic opportunities.

5 **Methods:** We conducted a comprehensive study including genome-wide and transcriptome-wide 6 association analyses to identify genetic loci associated with immunoglobulin G antibody response to 28 7 antigens for 16 viruses using serological data from 7924 European ancestry participants in the UK Biobank 8 cohort.

9 Results: Signals in human leukocyte antigen (HLA) class II region dominated the landscape of viral 10 antibody response, with 40 independent loci and 14 independent classical alleles, 7 of which exhibited 11 pleiotropic effects across viral families. We identified specific amino acid (AA) residues that are associated 12 with seroreactivity, the strongest associations presented in a range of AA positions within DRB1 at positions 11, 13, 71, and 74 for Epstein-Barr Virus (EBV), Varicella Zoster Virus (VZV), Human Herpes 13 14 virus 7, (HHV7) and Merkel cell polyomavirus (MCV). Genome-wide association analyses discovered 7 novel genetic loci outside the HLA associated with viral antibody response (P<5.0×10⁻⁸), including FUT2 15 (19q13.33) for human polyomavirus BK (BKV), STING1 (5q31.2) for MCV, as well as CXCR5 (11q23.3) 16 and TBKBP1 (17q21.32) for HHV7. Transcriptome-wide association analyses identified 114 genes 17 18 associated with response to viral infection. 12 outside of the HLA region, including ECSCR: P=5.0×10⁻¹⁵ (MCV), NTN5: P=1.1×10⁻⁹ (BKV), and P2RY13: P=1.1×10⁻⁸ EBV nuclear antigen. We also demonstrated 19 20 pleiotropy between viral response genes and complex diseases; from autoimmune disorders to cancer to 21 neurodegenerative and psychiatric conditions.

Conclusions: Our study confirms the importance of the HLA region in host response to viral infection and
 elucidates novel genetic determinants beyond the HLA that contribute to host-virus interaction.

24 KEY WORDS

- 25 Infection, virus, serology, antigen, antibody, immunoglobulin G, immune response, human leukocyte
- 26 antigen (HLA), polyomavirus, genome-wide association study (GWAS), transcriptome-wide association
- 27 study (TWAS)

28 INTRODUCTION

29 Viruses have been infecting cells for a half a billion years¹. During our extensive co-evolution viruses have exerted significant selective pressure on humans and vice versa; overtly during fatal outbreaks, and covertly 30 31 through cryptic immune interaction when a pathogen remains latent. The recent pandemic of severe acute 32 respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the paramount public health need to understand human genetic variation in response to viral challenge. Clinical variation in COVID-19 severity 33 34 and symptomatic presentation may be due to differences host genetic factors relating to immune response². Furthermore, many common infections are cryptically associated with a variety of complex illnesses, 35 36 especially those with an immunologic component, from cancer to autoimmune and neurologic conditions³⁻ ⁵. Despite their broad health relevance, few large-scale genome-wide association studies (GWAS) have 37 been conducted on serological response phenotypes⁶⁻¹⁰. Understanding the genetic architecture of 38 39 immunologic response to viruses may therefore provide new insight into etiologic mechanisms of diverse complex diseases. 40

Several common viruses exert a robust cell mediated and humoral immune response that bi-directionally modulate the balance between latent and lytic infection. Studies have demonstrated a strong heritable component (32-48%) of antibody response¹¹ and identified associations between host polymorphisms in genes relating to cell entry, cytokine production, and immune response and a variety of viruses¹². The predominance of previously reported associations with have implicated genetic variants in human leucocyte antigen (HLA) class I and II genes in the modulation of immune response to diverse viral antigens^{7,13}.

In this study we utilize data from the UK Biobank (UKB) cohort¹⁴ to evaluate the relationship between host genetics and immunoglobulin G antibody response to 28 antigens for 16 viruses. Immunoglobulin G (IgG) antibody is the most common antibody in blood, which serves as a stable biomarker of lifetime exposure to common viruses. High levels of specific IgG's can be the result of chronic infection, while low levels may indicate poor immunity. Viruses assayed in the UKB multiplex serology panel were previously chosen based on putative links to chronic diseases including cancer, autoimmune, and neurodegenerative conditions¹⁵. We conduct integrative genome-wide and transcriptome-wide analyses of antibody response and positivity

to viral antigens (Figure 1), which elucidate novel genetic underpinnings of viral infection and immune
 response.

56 METHODS

57 Study Population and Phenotypes

The UK Biobank (UKB) is a population-based prospective cohort of over 500,000 individuals aged 40-69 58 years at enrollment in 2006-2010 who completed extensive questionnaires, physical assessments, and 59 provided blood samples¹⁴. Analyses were restricted to individuals of predominantly European ancestry 60 61 based on self-report and after excluding samples with any of the first two genetic ancestry principal 62 components (PCs) outside of 5 standard deviations (SD) of the population mean (Supplementary Figure 63 1). We removed samples with discordant self-reported and genetic sex, samples with call rates <97% or heterozygosity >5 SD from the mean, and one sample from each pair of first-degree relatives identified 64 using KING¹⁶. 65

Of the 413,810 European ancestry individuals available for analysis, a total of 7948 had serological 66 67 measures. A multiplex serology panel (IgG) was performed over a 2-week period using previously developed methods^{17,18} that have been successfully applied in epidemiological studies^{7,19}. Details of the 68 serology methods and assay validation performance are described in Mentzer et al.¹⁵ Briefly, multiplex 69 70 serology was performed using a bead-based glutathione S-transferase (GST) capture assay with glutathione-casein coated fluorescence-labelled polystyrene beads and pathogen-specific GST-X-tag 71 fusion proteins as antigens¹⁵. Each antigen was loaded onto a distinct bead set and the beads were 72 simultaneously presented to primary serum antibodies at serum dilution 1:1000¹⁵. Immunocomplexes were 73 74 quantified using a Luminex 200 flow cytometer, which produced Median Fluorescence Intensities (MFI) for 75 each antigen. The serology assay showed adequate performance, with a median coefficient of variation (CV) of 17% across all antigens and 3.5% among seropositive samples only¹⁵. 76

77 Genome-Wide Association Analysis

We evaluated the relationship between genetic variants across the genome and serological phenotypes
 using PLINK 2.0 (October 2017 version). Participants were genotyped on the Affymetrix Axiom UK Biobank

array (89%) or the UK BiLEVE array $(11\%)^{14}$ with genome-wide imputation performed using the Haplotype Reference Consortium data and the merged UK10K and 1000 Genomes phase 3 reference panels¹⁴. We excluded variants out of Hardy-Weinberg equilibrium at p<1×10⁻⁵, call rate <95% (alternate allele dosage within 0.1 of the nearest hard call to be non-missing), imputation quality INFO<0.30, and MAF<0.01.

Seropositivity for each antigen was determined using established cut-offs based on prior validation work¹⁵. The primary GWAS focused on continuous phenotypes (MFI values), which measure the magnitude of antibody response, also referred to as seroreactivity. These analyses were conducted among seropositive individuals only for antigens with seroprevalence of \geq 20% (n=1500) based on 80% power to detect only common variants with large effect sizes at this sample size (**Supplementary Figure 2**). MFI values were transformed to standardized, normally distributed z-scores using ordered quantile normalization²⁰.

Seroreactivity GWAS was conducted using linear regression with adjustment for age at enrollment, sex, 90 91 body-mass index (BMI), socioeconomic status (Townsend deprivation index), the presence of any autoimmune and/or inflammatory conditions, genotyping array, serology assay date, quality control flag 92 indicating sample spillover or an extra freeze/thaw cycle, and the top 10 genetic ancestry principal 93 components (PC's). Autoimmune and chronic inflammatory conditions were identified using the following 94 95 primary and secondary diagnostic ICD-10 codes (E10, M00-03, M05-M14, M32, L20-L30, L40, G35, K50-52, K58, G61) in Hospital Episode Statistics. Individuals diagnosed with any immunodeficiency (ICD-10 96 97 D80-89, n=24) were excluded from all analyses.

For all antigens with at least 100 seropositive (or seronegative for pathogens with ubiquitous exposure)
 individuals, GWAS of discrete seropositivity phenotypes was undertaken using logistic regression, adjusting
 for the same covariates listed above.

The functional relevance of the lead GWAS loci for antibody response was assessed using in-silico functional annotation analyses based on Combined Annotation Dependent Depletion (CADD)²¹ scores and RegulomeDB 2.0²², and by leveraging external datasets, such as GTEx v8, DICE (Database of Immune Cell Expression)²³, and the Human Plasma Proteome Atlas^{24,25}.

105

106 Cross-Trait Associations with Disease

We explored pleiotropic associations between lead variants influencing antibody levels and several chronic 107 diseases with known or hypothesized viral risk factors. Associations with selected cancers were obtained 108 109 from a cancer pleiotropy meta-analysis of the UK Biobank and Genetic Epidemiology Research on Aging 110 cohorts²⁶. Summary statistics for the schizophrenia GWAS of 33,640 cases and 43,456 controls by Lam et 111 al.²⁷ were downloaded from the Psychiatric Genomics Consortium. Association p-values were obtained from the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site for the GWAS by 112 Jun et al.²⁸, which included 17,536 cases and 53,711 controls. Associations with p<7.3×10⁻⁴ were 113 considered statistically significant after correction for the number of variants and phenotypes tested. 114

115 HLA Regional Analysis

For phenotypes displaying a genome-wide significant signal in the HLA region, independent association signals were ascertained using two complementary approaches: clumping and conditional analysis. Clumping is a post-processing step applied to GWAS summary statistics to identify independent association signals by grouping variants based on LD within specific windows. Clumping was performed on all variants with $P < 5 \times 10^{-8}$ for each phenotype, as well as across phenotypes. Clumps were formed around index variants with the lowest p-value and all other variants with LD $r^2 > 0.05$ within a ±500 kb window were considered non-independent and assigned to that variant's clump.

123 Next, we conducted conditional analyses using a forward stepwise strategy to identify statistically independent signals within each type of variant (SNP/indel or classical HLA allele). Unlike clumping, 124 conditional analyses involve fitting a new model that includes specific variants as covariates, thereby 125 126 directly accounting for LD and providing association estimates that are adjusted for other relevant SNP effects. A total of 38,655 SNPs/indels on chromosome 6 (29,600,000 - 33,200,000 bp) were extracted to 127 conduct regional analyses. Classical HLA alleles were imputed for UKB participants at 4-digit resolution 128 using the HLA*IMP:02 algorithm¹⁴, with modified settings to accommodate the addition of diverse samples 129 from population reference panels described by Motyer et al.²⁹. Details of the HLA imputation procedure are 130 described in UKB Resource 182. Imputed dosages were available for 362 classical alleles in 11 genes: 131

HLA-A, HLA-B, and HLA-C (class I); HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 (class II). Allele names with "99:01" for DRB3/4/5, which denote copy
number absence, were renamed as "00:00" to avoid confusion with traditional HLA nomenclature. We also
used SNP2HLA³⁰ to impute HLA alleles and corresponding amino acid sequences at a four-digit resolution
in HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB1 using the Type
1 Diabetes Genetics Consortium (T1DGC) reference panel comprised of 2,767 unrelated individuals of
European descent. T1DGC was also among several reference datasets used by HLA*IMP:02.

Analyses were restricted to common HLA alleles and amino acid sequences (frequency ≥ 0.01) with imputation quality scores >0.30, for a total of 1081 markers (101 alleles + 980 amino acid residues). Linear regression models were adjusted for the same set of covariates as the GWAS. Associations for each marker were considered statistically significant if *P*<4.6×10⁻⁵ based on Bonferroni correction for 1081 tests.

For each antigen response phenotype, we identified SNPs/indels or classical HLA alleles with the lowest p-value, among variants that achieved Bonferroni-significant associations (P<4.6×10⁻⁵), and performed forward iterative conditional regression to identify other independent signals, until no associations with a conditional p-value (P_{cond})<5×10⁻⁸ remained. We also assessed the independence of associations across different types of genetic variants by including conditionally independent HLA alleles as covariates in the SNP-based analysis.

For amino acid positions with >2 possible residues (alleles), we applied the haplotype omnibus test to obtain an overall p-value for jointly testing all possible substitutions at that specific position. The omnibus test was applied to all amino acid residues at a given position, even if not all substitutions achieved the Bonferronicorrected threshold (P<4.6×10⁻⁵) in the single-marker analysis. The frequency of amino acid substitutions at specific HLA alleles was determined using European ancestry reference populations part of the Allele Frequency Net Database (AFND 2020)³¹.

155

156

157

158 Transcriptome-Wide Association Analysis

Gene transcription levels were imputed and analyzed using the MetaXcan approach³², applied to GWAS 159 summary statistics for quantitative antigen phenotypes. For imputation, we used biologically informed 160 MASHR-M prediction models³³ based on GTEx v8 with effect sizes computed using MASHR (Multivariate 161 162 Adaptive Shrinkage in R)³⁴ for variants fine-mapped with DAP-G (Deterministic Approximation of Posteriors)^{35,36}. An advantage of this approach is that MASHR effect sizes are smoothed by taking 163 advantage of the correlation in cis-eQTL effects across tissues. For each antigen, we performed a 164 transcriptome-wide association study (TWAS) using gene expression levels in whole blood. Statistically 165 significant associations for each gene were determined based on Bonferroni correction for the number of 166 167 genes tested.

We also examined gene expression profiles in tissues that represent known infection targets or related pathologies. Human herpesviruses and polyomaviruses are neurotropic and have been implicated in several neurological conditions^{37,38}, therefore we considered gene expression in the frontal cortex. For Epstein-Barr virus (EBV) antigens additional models included EBV-transformed lymphocytes. Merkel cell polyomavirus (MCV) is a known cause of Merkel cell carcinoma³⁹, a rare but aggressive type of skin cancer, therefore we examined transcriptomic profiles in skin tissues for MCV only.

Pathways represented by genes associated with antibody response to viral antigens were summarized by conducting enrichment analysis using curated Reactome gene sets and by examining protein interaction networks using the STRING database⁴⁰. Significantly associated TWAS genes were grouped by virus family (herpesviruses vs. polyomaviruses) and specificity of association (multiple antigens vs. single antigen).

178 **RESULTS**

A random sample of the participants representative of the full UKB cohort was assayed using a multiplex serology panel¹⁵. We analyzed data from 7924 participants of predominantly European ancestry, described in **Supplementary Table 1**. Approximately 90% of individuals were seropositive for herpes family viruses with ubiquitous exposure: EBV (EBV EA-D: 86.2% to ZEBRA: 91.2%), Human Herpesvirus 7 (HHV7 94.8%), and Varicella Zoster Virus (VZV 92.3%). Seroprevalence was somewhat lower for cytomegalovirus

(CMV), ranging between 56.5% (CMV pp28) and 63.3% (CMV pp52), and Herpes Simplex virus-1 (HSV1
69.3%). Human polyomavirus BKV was more prevalent (95.3%) compared to other polyomaviruses, Merkel
cell polyoma virus (MCV 66.1%) and polyomavirus JC (JCV) (56.6%). Less common infections included
HSV-2 (15.2%), HPV16 (E6 and E7 oncoproteins: 4.7%), HPV18 (2.4%), Human T-cell lymphotropic virus
type 1 (HTLV1, 1.6%), Hepatitis B (HBV, 1.6%), and Hepatitis C (HCV, 0.3%).

189 Genetic Determinants of Response to Viral Infection

190 Results from our GWAS of antibody response phenotypes were dominated by signals in the HLA region, 191 which were detected for all EBV antigens (EA-D, EBNA, p18, ZEBRA), CMV pp52, HSV1, HHV7, VZV, JCV 192 and MCV (Table 1; Supplementary Figure 3). Most of the top-ranking HLA variants for each antigen were 193 independent of those for other antigens based on r^2 but not D' (Supplementary Figure 4). Exceptions were moderate LD between lead variants for EBV ZEBRA and HSV1 (r^2 =0.45), EBV EBNA and JCV (r^2 =0.45), 194 195 and HHV7 and MCV (r^2 =0.44). However, based on the complex LD structure and effect sizes, we cannot 196 rule out that these linked to rare haplotypes. Outside of the HLA region, genome-wide significant 197 associations with seroreactivity were detected for: MCV at 3p24.3 (rs776170649, LOC339862: P=1.7×10⁻ ⁸) and 5q31.2 (rs7444313, *TMEM173* (also known as *STING1*): *P*=2.4×10⁻¹⁵); BKV at 19q13.3 (rs681343, 198 199 FUT2: P=4.7×10⁻¹⁵) (Figure 2); EBV EBNA at 3q25.1 (rs67886110, MED12L: P=1.3×10⁻⁹); HHV-7 at 11q23.3 (rs75438046, CXCR5: P=1.3×10⁻⁸) and 17q21.3 (rs1808192, TBKBP1: P=9.8×10⁻⁹); and HSV-1 at 200 10q23.3 (rs11203123: P=3.9×10-8). However, the loci outside of HLA identified for HHV7 and HSV1 were 201 not statistically significant considering a more stringent significance threshold corrected for the number of 202 seroreactivity phenotypes tested ($P < 5.0 \times 10^{-8}/16 = 3.1 \times 10^{-9}$). 203

GWAS of discrete seropositivity phenotypes identified associations in HLA for EBV EA-D (rs2395192: OR=0.66, P=4.0×10⁻¹⁹), EBV EBNA (rs9268848: OR=1.60, P=1.2×10⁻¹⁸), EBV ZEBRA (rs17211342: 0.63, P=1.6×10⁻¹⁵), VZV (rs3096688: OR=0.70, P=3.7×10⁻⁸), JCV (rs9271147: OR=0.54, P=1.3×10⁻⁴²), and MCV (rs17613347: OR=0.61, P=1.2×10⁻²⁶) (**Supplementary Figure 2; Supplementary Table 3**). An association with susceptibility to MCV infection was also observed at 5q31.2 (rs1193730215, *ECSCR*: OR=1.26, P=7.2×10⁻⁹), with high LD (r^2 =0.95) between seroreactivity and seropositivity lead variants.

210 Several genome-wide significant associations were observed for antigens with <20% seroprevalence, 211 which were not included in the GWAS of antibody response due to inadequate sample size 212 (Supplementary Table 3). Infection susceptibility variants were identified for HSV2 in 17p13.2 (rs2116443: OR=1.28, P=4.5×10⁻⁸; ITGAE); HPV16 E6 and E7 oncoproteins in 6p21.32 (rs601148: OR=0.60, P=3.3×10⁻ 213 ⁹; *HLA-DRB1*) and 19q12 (rs144341759: OR=0.383, *P*=4.0×10⁻⁸; *CTC-448F2.6*); and HPV18 in 14q24.3 214 (rs4243652: OR=3.13, P=7.0×10⁻¹⁰). Associations were also detected for Kaposi's sarcoma-associated 215 216 herpesvirus (KSHV), HTLV1, HBV and HCV, including a variant in the MERTK oncogene (HCV Core 217 rs199913364: OR=0.25, $P=1.2\times10^{-8}$). After correcting for 28 serostatus phenotypes tested ($P<1.8\times10^{-9}$), the only statistically significant associations remained for EBV EA-D (rs2395192), EBV EBNA (rs9268848), 218 EBV ZEBRA (rs17211342), JCV (rs9271147), MCV (rs17613347), and HPV18 (rs4243652). 219

220 Functional Characterization of GWAS Findings

In-silico functional analyses of the lead 17 GWAS variants identified enrichment for multiple regulatory elements (summarized in **Supplementary Table 4**). Three variants were predicted to be in the top 10% of deleterious substitutions in GRCh37 based on CADD scores >10: rs776170649 (MCV, CADD=15.61), rs139299944 (HHV7, CADD=12.15), and rs9271525 (JCV, CADD=10.73). Another HHV7-associated variant, rs1808192 (RegulomeDB rank: 1f), an eQTL and sQTL for *TBKBP1*, mapped to 44 functional elements for multiple transcription factors, including IKZF1, a critical regulator of lymphoid differentiation frequently mutated in B-cell malignancies.

Eleven sentinel variants were eQTLs and 8 were splicing QTLs in GTEx, with significant (FDR<0.05) effects 228 229 across multiple genes and tissues (Supplementary Figure 5). The most common eQTL and sQTL targets 230 included HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, and HLA-DRB6. Outside of HLA, 231 rs681343 (BKV), a synonymous FUT2 variant was an eQTL for 8 genes, including FUT2 and NTN5. MCV 232 variant in 5q31.2, rs7444313, was an eQTL for 7 genes, with concurrent sQTL effects on TMEM173, also known as STING1 (stimulator of interferon response cGAMP interactor 1) and CXXC5. Gene expression 233 profiles in immune cell populations from DICE²³ identified several cell-type specific effects that were not 234 observed in GTEx. An association with HLA-DQB1 expression in CD4+ T_H2 cells was observed for 235

rs9273325, 6:31486158_GT_G was an eQTL for *ATP6V1G2* in naïve CD4+ T cells, and rs1130420
 influenced the expression of 8 HLA class II genes in naïve B-cells and CD4+ T_H17 cells.

We identified 7 significant (p<5.0×10⁻⁸) protein quantitative trait loci (pQTL) for 38 proteins (**Supplementary Table 5**). Most of the pQTL targets were components of the adaptive immune response, such as the complement system (C4, CFB), chemokines (CCL15, CCL25), and defensin processing (Beta-defensin 19, Trypsin-3). The greatest number and diversity of pQTL targets (n=16) was observed for rs681343, including BPIFB1, which plays a role in antimicrobial response in oral and nasal mucosa⁴¹; FUT3, which catalyzes the last step of Lewis antigen biosynthesis; and FGF19, part of the PI3K/Akt/MAPK signaling cascade that is dysregulated in cancer and neurodegenerative diseases⁴².

245 Cross-trait associations with disease outcomes

246 To contextualize the relevance of genetic loci involved in infection response, we explored associations with selected cancers, schizophrenia, and that have a known or suspected viral etiology (Supplementary Table 247 6). The strongest secondary signal was observed for rs9273325 (HLA-DQB1), which was negatively 248 249 associated with VZV antibody response and positively associated with schizophrenia susceptibility $(OR=1.13, P=4.3\times10^{-15})$. Other significant (Bonferroni P<7.4×10⁻⁴) associations with schizophrenia were 250 detected for HSV1 (rs1130420: OR=1.06, P=1.8×10⁻⁵), EBV EA-D (rs2647006: OR=0.96, P=2.7×10⁻⁴), JCV 251 (rs9271525: OR=1.06, P=6.8×10⁻⁵) and BKV (rs681343: OR=0.96, P=2.5×10⁻⁴), with the latter being the 252 253 only pleiotropic signal outside of HLA. Inverse associations with hematologic cancers were observed for 254 HSV1 (rs1130420: OR=0.89, P=3.5×10⁻⁶), VZV (rs9273325: OR=0.88, P=4.4×10⁻⁵), and EBV EBNA (rs9269233: OR=0.88, P=2.7×10⁻⁴) variants. HSV1 antibody response was also linked to Alzheimer's 255 256 disease (rs1130420: P=1.2×10⁻⁴).

257 Regional HLA Associations

Associations within the HLA region were refined by identifying independent (LD r^2 <0.05 within ±500kb) index variants with P<5.0×10⁻⁸ for each antigen response phenotype (**Supplementary Table 7**). Clumping seropositivity associations with respect to lead antibody response variants did not retain any loci,

suggesting non-independence in signals for infection and reactivity for the same antigen. For this reason, 261 262 all subsequent analyses focus on seroreactivity phenotypes. Clumping across phenotypes to assess the independence of HLA associations for different antigens identified 40 independent index variants; EBV 263 EBNA (12), VZV (11), EBV ZEBRA (8), EBV p18 (5), MCV (3), and EBV EA-D (1) (Supplementary Table 264 9). No LD clumps were anchored by variants detected for CMV pp52, HHV7, HSV1, or JCV, suggesting 265 266 that the HLA signals for these antigens are captured by lead loci for other phenotypes. The largest region with the lowest p-value was anchored by rs9274728 ($P=4.7\times10^{-67}$) near HLA-DQB1, originally detected for 267 EBV ZEBRA. Of the 11 VZV-associated variants, the largest clump was formed around rs4990036 268 (P=4.5×10⁻²⁶) in HLA-B. 269

Iterative conditional analyses adjusting for the HLA SNP/indel with the lowest p-value were performed until
no variants remained with *P*_{cond}<5.0×10⁻⁸. Additional independent variants were identified for EBV EBNA
(rs139299944, rs6457711, rs9273358, rs28414666, rs3097671), EBV ZEBRA (rs2904758, rs35683320,
rs1383258), EBV p18 (rs6917363, rs9271325, rs66479476), and MCV (rs148584120, rs4148874) (Figure **3; Supplementary Table 8**). For CMV pp52, HHV7, HSV1, JCV, and VZV, the regional HLA signal was
captured by the top GWAS variant (Figure 2; Supplementary Table 8).

Next, we tested 101 classical HLA alleles and performed analogous iterative conditional analyses for 276 significantly associated variants (P<4.6×10⁻⁵). To help with the interpretation of our results, we depict the 277 278 LD structure for HLA alleles in class II genes in Supplementary Figure 5. Significant associations across 279 viruses were predominantly observed for class II HLA alleles. Five statistically independent signals were identified for antibody response to EBV ZEBRA (DRB4*00:00: β =-0.246, P=1.4×10⁻⁴⁶; DQB1*04:02: 280 281 $\beta_{cond}=0.504$, $P_{cond}=1.0\times10^{-19}$; DRB1*04:04: $\beta_{cond}=0.376$, $P_{cond}=1.1\times10^{-18}$; DQA1*02:01: $\beta_{cond}=0.187$, $P_{\text{cond}}=1.1\times10^{-10}$, A*03:01: $\beta_{\text{cond}}=0.129$, $P_{\text{cond}}=1.9\times10^{-8}$) (Figure 3; Supplementary Table 11). DRB4*00:00 282 represents copy number absence, which co-occurs with DRB1*04 and DRB1*07 alleles⁴³. This is consistent 283 284 with the magnitude and direction of unconditional associations observed for DRB1*07:01 (β =0.251, $P=1.3\times10^{-26}$) and DRB4*04:01 ($\beta=0.293$, $P=7.9\times10^{-22}$). Five conditionally independent alleles were also 285 identified for EBV EBNA: DRB5*00:00: β=-0.246, P=8.7×10⁻³⁰; DRB3*02:02: β_{cond}=0.276, P_{cond}=6.8×10⁻³⁰; 286 DQB1*02:01: β_{cond}=-0.164, P_{cond}=3.6×10⁻¹²; DRB4*00:00: β=0.176, P_{cond}=8.3×10⁻¹⁷; DPB1*03:01: β_{cond}=-287

12

288 0.220, P_{cond} =4.7×10⁻¹⁴ (Figure 3; Supplementary Table 11). DRB5*00:00 denotes a copy number deletion 289 that sits on an common haplotype comprised of DRB1*15:01, DQB1*06:02, DQA1*01:02⁴³, which may also 290 include DRB5*01:01⁴⁴ (Supplementary Figure 6). The presence of the DRB1*15:01-DQB1*06:02-291 DQA1*01:02 haplotype was associated with increased EBV EBNA seroreactivity (β =0.330, P=2.5×10⁻²⁸). 292 Fewer independent alleles were observed for EBV p18 (DRB5*00:00: β =-0.210, P=1.7×10⁻²²; DRB1*04:04: 293 β_{cond} =0.357, P_{cond} =1.3×10⁻¹⁸) (Figure 3; Supplementary Tables 12).

294 DQB1*02:01 was the only independently associated allele for EBV EA-D (β =-0.154, P=8.4×10⁻¹¹) and HSV1 (β =0.145, *P*=2.8×10⁻⁸), although its effects were in opposite directions for each antigen (**Supplementary** 295 296 **Table 13**). For VZV, associations with 16 classical alleles were accounted for by DRB1*03:01 (β =0.236, P=7.3×10⁻²⁶). JCV shared the same lead allele as EBV EBNA and EBV p18 (DRB5*00:00: β =0.350, 297 P=1.2×10⁻²¹) (Supplementary Table 13). Four conditionally independent signals were identified for MCV 298 (DQA1*01:01: β=0.215, P=1.1×10⁻¹⁵; DRB1*04:04: βcond=-0.362, Pcond=3.0×10⁻¹¹; A*29:02: βcond=-0.350, 299 $P=1.0\times10^{-11}$; DRB1*15:01: $\beta_{cond}=-0.203$, $P=3.7\times10^{-12}$) (Figure 3; Supplementary Table 14). Lastly, we 300 integrated associations across variant types by including conditionally independent HLA alleles as 301 302 covariates in the SNP-based analysis. With the exception of EBV antigens and HHV7, classical HLA alleles 303 captured all genome-wide significant SNP signals (Supplementary Figure 7).

Finally, we tested 980 HLA amino acid substitutions (**Supplementary Tables 15-24**), followed by omnibus haplotype tests at each position that had a significant amino acid and more than two possible alleles. The strongest allele-specific and haplotype associations were found at different positions in the same protein for EBV p18 (DR β 1 Ala -17: β =-0.194, *P*=1.0×10⁻²¹; DR β 1 (13): *P*_{omni}=4.6×10⁻²²), MCV (DQ β 1 Leu-26: β =-0.173, *P*=7.0×10⁻¹⁸; DQ β 1 (125): *P*_{omni}=2.0×10⁻¹⁷), HHV7 (DQ β 1 His-30: β =-0.111, *P*=1.2×10⁻⁸; DQ β 1 (57): *P*_{omni}=5.6×10⁻⁹), and HHV6 IE1B at (DR β 1 Ile-67: β =0.131, *P*=1.6×10⁻⁸; DR β 1 (13): *P*_{omni}=1.1×10⁻⁵).

The strongest residue-specific and haplotype associations mapped to the same amino acid position for four phenotypes: EBV ZEBRA (**Supplementary Table 18**), HHV6 IE1A (**Supplementary Table 19**), HSV1 (**Supplementary Table 21**), and JCV (**Supplementary Table 23**). Amino acid residues at DQ α 1 (175) were associated with antibody response to EBV ZEBRA (Glu: β =0.279, *P*=1.1×10⁻⁶¹; *P*_{omni}=8.3×10⁻⁶²). Glu-175 is present in DQA1*02:01 (P=4.9×10⁻²⁷), DQA1*03:01 (P=1.3×10⁻¹⁶), DQA1*04:01 (P=1.9×10⁻¹²), and seems to better summarize the EBV ZEBRA signal at this locus. Substitutions in DR β 1 (96) contained the strongest predictors of JCV seroreactivity (His or Tyr: β =0.325, P=1.6×10⁻²⁵; P_{omni} =7.7×10⁻²³). His-96/Tyr-96 are in high LD (r^2 =0.92) with DRB5*00:00, the top JCV-associated allele. However, this might mask the signal for Gln-96 (β =-0.310, P=9.0×10⁻²³), which is part of the DRB1*15:01 sequence (β =-0.309, P=9.0×10⁻²¹; LD r^2 =0.94). The lead signal for HSV1 mapped to DQ β 1 (57) (Ala: β =0.123, P=2.2×10⁻¹⁰; P_{omni} =6.5×10⁻⁹), which aligns with the association for the lead HSV1-allele DQB1*02:01.

For EBV EBNA the strongest haplotype association was in DR β 1 (37) (P_{omni} =1.1×10⁻⁵⁵), while the residue 321 322 with the lowest p-value was DQ β 1 Ala-57 (β =-0.237, P=1.4×10⁻⁴²) (Supplementary Table 16). Ala-57 maps 323 to multiple DQB1 alleles and achieved a stronger signal for EBV EBNA than any classical HLA allele. Asp-9 in HLA-B showed the strongest association with antibody response to EBV EA-D (β =-0.146, P=1.8×10⁻⁹; 324 Supplementary Table 15) and VZV (β =0.237, P=9.7×10⁻²⁵: Supplementary Table 22). This amino acid 325 sequence is part of B*08:01, which had analogous effects on both phenotypes (EBV EA-D: ß=-0.144. 326 $P=2.7\times10^{-9}$; VZV: $\beta=0.238$, $P=4.7\times10^{-25}$). Haplotypes with the lowest overall p-values were found in DQ β 1 327 (71) for VZV ($P_{omni}=9.8\times10^{-19}$) and DRB1 (11) for EBV EA-D ($P_{omni}=1.7\times10^{-10}$). 328

329 TWAS of Genes Involved in Antibody Response

Based on known targets of infection or related pathologies, we considered expression in the frontal cortex (Supplementary Table 25), EBV-transformed lymphocytes for EBV antigens (Supplementary Table 26), and skin for MCV (Supplementary Table 27). Concordance across tissues was summarized using Venn diagrams (Figure 4; Supplementary Figure 8). TWAS identified 114 genes significantly associated $(P_{TWAS} < 4.2 \times 10^{-6})$ with antibody response in at least one tissue, 54 of which were associated with a single phenotype, while 60 influenced seroreactivity to multiple antigens. We also include results for 87 additional suggestively ($P_{TWAS} < 4.2 \times 10^{-5}$) associated genes.

The TWAS results included a predominance of associations in HLA class II genes. Some of the strongest overall associations were observed for *HLA-DRB5* (EBV ZEBRA: P_{cortex} =4.2×10⁻⁴⁵) and *HLA-DRB1* (EBV EBNA: P_{cortex} =6.7×10⁻³⁹; EBV ZEBRA: P_{cortex} =3.3×10⁻³³; JCV: P_{cortex} =6.5×10⁻¹⁴; EBV p18: P_{cortex} =2.2×10⁻¹²).

Increased expression of *HLA-DQB2* was positively associated with antibody response to EBV ZEBRA $(P_{blood}=7.6\times10^{-19})$, JCV $(P_{blood}=9.9\times10^{-10})$, VZV $(P_{blood}=7.0\times10^{-9})$, HHV7 $(P_{blood}=7.3\times10^{-8})$, and HSV1 $(P_{blood}=3.3\times10^{-7})$, but negatively associated with EBV EBNA $(P_{blood}=3.6\times10^{-34})$ and EBV p18 $(P_{blood}=2.1\times10^{-34})$ ⁸), in a consistent manner across tissues. The opposite was observed for *HLA-DQB1*, with positive effects on EBV EBNA and EBV p18 and inverse associations with EBV ZEBRA, JCV, VZV, HHV7, and HSV1.

345 The TWAS analyses also identified a number of significant associations in the HLA class III region that were not detected in other analyses. The top-ranking VZV associated gene was APOM (Pblood=7.5×10⁻²⁷, 346 P_{cortex} =1.1×10⁻²⁵). Interestingly, opposite directions of effect were observed for C4A and C4B gene 347 348 expression. Increased C4A expression was positively associated with all EBV antigens (Supplementary Table 26), but negatively associated with VZV (P_{blood}=2.3×10⁻²⁴) and HSV1 (P_{cortex}=1.8×10⁻⁵) antibody levels 349 350 (Supplementary Table 25). On the other hand, increased C4B expression was inversely associated with EBV phenotypes, but positively associated with VZV (Pblood=8.1×10⁻²⁵) and HSV1 (Pblood=1.1×10⁻⁵). A similar 351 pattern was also observed for CYP21A2 and C2, with positive effects on antibody response to VZV and 352 HSV1, and negative effects for all EBV antigens. Other novel TWAS findings were detected for HHV7 in 353 22q13.2 (CTA-223H9.9: PTWAS=2.5×10⁻⁶; CSDC2: PTWAS=3.0×10⁻⁶; TEF: PTWAS=3.1×10⁻⁶) and 1q31.2 354 (RGS1: P_{TWAS}=3.3×10⁻⁶). 355

The TWAS recapitulated several GWAS-identified loci: 3q25.1 for EBV EBNA (P2RY13: Pcortex=1.1×10⁻⁸; 356 P2RY12: Pblood=3.3×10⁻⁸) and 19q13.33 for BKV (FUT2: PTWAS=8.1×10⁻¹³; NTN5: PTWAS=1.1×10⁻⁹). 357 Transcriptomic profiles in skin tissues provided supporting evidence for the role of multiple genes in 5q31.2 358 in modulating MCV antibody response (Figure 4; Supplementary Table 27). The strongest signal was 359 observed in for ECSCR (skin sun unexposed: PTWAS=5.0×10⁻¹⁵; skin sun exposed: PTWAS=4.2×10⁻¹³), 360 followed by PROB1 (sun unexposed: PTWAS=1.5×10⁻¹¹). ECSCR expression was also associated based on 361 expression in the frontal cortex, while PROB1 exhibited a significant, but attenuated effect in whole blood. 362 363 VWA7 was the only gene associated across all four tissues for MCV and was also associated with antibody 364 response to several EBV antigens.

Comparison of results for seroreactivity and seropositivity revealed a number of genes implicated in both steps of the infection process (**Supplementary Table 28**). Associations with HLA DQA and DQB genes in whole blood and HLA-DRB genes in the frontal cortex were observed for EBV antigens, JCV, and MCV. For MCV, the strongest seropositivity signals were observed for HLA class III genes AGER ($P_{cortex}=9.0\times10^{-10}$) and *EHMT2* ($P_{blood}=5.8\times10^{-18}$), which were also among the top-ranking genes for seroreactivity. Increased *ECSCR* expression conferred an increased susceptibility to MCV infection ($P_{cortex}=1.8\times10^{-8}$), mirroring its effect on seroreactivity. In contrast to antibody response, no significant associations with any HLA genes were observed for VZV seropositivity.

Analyses using the Reactome database identified significant ($q_{FDR}<0.05$) enrichment for TWAS-identified genes in pathways involved in initiating antiviral responses, such as MHC class II antigen presentation, TCR signaling, and interferon (IFN) signaling (**Supplementary Figure 9**). Pathways unique to herpesviruses included folding, assembly and peptide loading of class I MHC ($q=3.2\times10^{-7}$) and initial triggering of complement ($q=9.8\times10^{-3}$). Polyomaviruses were associated with the non-canonical nuclear factor (NF)- κ B pathway activated by tumor necrosis factor (TNF) superfamily ($q=1.9\times10^{-3}$).

379 **DISCUSSION**

380 We performed genome-wide and transcriptome-wide association studies for serological phenotypes for 16 common viruses in a well-characterized, population-based cohort. We discovered novel genetic 381 determinants of viral antibody response beyond the HLA region for BKV, MCV, HHV7, EBV EBNA. 382 Consistent with previous studies^{7,8} we detected strong signals for immune response to diverse viral antigens 383 in the HLA region, with a predominance of associations observed for alleles and amino acids in HLA-DRB1 384 385 and HLA-DQB1, as well as transcriptome-level associations for multiple class II and III HLA genes. Taken together, the findings of this work provide a resource for further understanding the complex interplay 386 387 between viruses and the human genome, as well as a first step towards understanding genetic determinants of reactivity to common infections. 388

One of our main findings is the discovery of 5q31.2 as a susceptibility locus for MCV infection and MCV antibody response, implicating two main genes: *TMEM173* (or *STING1*) and *ECSCR*. The former encodes STING (stimulator of interferon genes), an endoplasmic reticulum (ER) protein that controls the transcription of host defense genes and plays a critical role in response to DNA and RNA viruses⁴⁵. STING is activated

16

by cyclic GMP-AMP synthase (cGAS), a cytosolic DNA sensor that mounts a response to invading 393 394 pathogens by inducing IFN1 and NF-κB signalling^{46,47}. Polyomaviruses penetrate the ER membrane during cell entry, a process that may be unique to this viral family⁴⁸, which may trigger STING signaling in a distinct 395 manner from other viruses⁴⁸. Multiple cancer-causing viruses, such as KSHV, HBV, and HPV18, encode 396 oncoproteins that disrupt cGAS-STING activity, which illustrates the evolutionary pressure on DNA tumor 397 viruses to develop functions against this pathway and its importance in carcinogenesis⁴⁶. Furthermore, 398 399 cGAS-STING activation has been shown to trigger antitumor T-cell responses, a mechanism that can be leveraged by targeted immunotherapies ⁴⁹⁻⁵¹. Several studies suggest STING agonists may be effective 400 against tumors resistant to PD-1 blockade, as well as promising adjuvants in cancer vaccines⁵²⁻⁵⁴. 401

ECSCR expression in skin and brain tissues was associated with MCV antibody response and infection.
This gene encodes an endothelial cell-specific chemotaxis regulator, which plays a role in angiogenesis
and apoptosis⁵⁵. *ECSCR* is a negative regulator of PI3K/Akt signaling by enhancing membrane localization
of *PTEN* and operates in tandem with VEGFR-2 and other receptor tyrosine kinases⁵⁶. In addition to 5q31.2,
another novel MCV seroreactivity associated region was identified in 3p24.3, anchored by rs776170649,
which has been linked to platelet phenotypes⁵⁷. These findings align with a role of platelet activation in
defense against infections via degranulation-mediated release of chemokines and β-defensin⁵⁸.

409 Genetic variation within Fucosyltransferase 2 (FUT2) has been studied extensively in the context of human 410 infections; however, its effect on BKV seroreactivity is novel. Homozygotes for the nonsense mutation 411 (rs601338 G>A) that inactivates the FUT2 enzyme are unable to secrete ABO(H) histo-blood group 412 antigens or express them on mucosal surfaces^{59,60}. The allele which confers increased BKV antibody response (rs681343-T) is in LD (r^2 =1.00) with rs601338-A, the non-secretor allele, which confers resistance 413 to norovirus^{61,62}, rotavirus⁶³, H. pylori⁶⁴, childhood ear infection, mumps, and common colds¹³. However, 414 increased susceptibility to other pathogens, such as meningococcus and pneumococcus⁶⁵ has also been 415 416 observed in non-secretors. Isolating the underlying mechanisms for BKV response is challenging because FUT2 is a pleiotropic locus associated with diverse phenotypes, including autoimmune and inflammatory 417 conditions^{66,67}, serum lipids⁶⁸, B vitamins^{60,69}, alcohol consumption⁷⁰, and even certain cancers⁷¹. In addition 418 419 to FUT2 in 19q13.33, NTN5 (netrin 5) suggests a possible link between BKV and neurological conditions.

NTN5 is primarily expressed in neuroproliferative areas, suggesting a role in adult neurogenesis, which is
 dysregulated in glioblastoma and Alzheimer's disease^{72,73}.

422 We also report the first GWAS of serological phenotypes for HHV7. Genetic determinants of HHV7 antibody 423 response in 6p21.32 were predominantly localized in HLA-DQA1 and HLA-DQB1, with associations similar 424 to other herpesviruses. In 11g23.3, rs75438046 maps to the 3' UTR of CXCR5, which controls viral infection in B-cell follicles⁷⁴, and BCL9L, a translocation target in acute lymphoblastic leukemia⁷⁵ and transcriptional 425 activator of the Wnt/ β -catenin cancer signaling pathway⁷⁶. In 17g21.32, TBKBP1 encodes an adaptor 426 protein that binds to TBK1 and is part of the TNF/NF-κB interaction network, where it regulates immune 427 428 responses to infectious triggers, such as IFN1 signaling⁷⁷. Interestingly, a protein interactome map recently 429 revealed that SARS-CoV-2 nonstructural protein 13 (Nsp13) includes TBK1-TBKBP1 among its targets ⁷⁸. 430 Other functions of the TBK1-TBKBP1 axis relate to tumor growth and immunosuppression through induction of PD-L179. 431

Several additional genes involved in HHV7 immune response were identified in TWAS. *TEF* in 22q13.2 is an apoptotic regulator of hematopoietic progenitors with tumor promoting effects mediated by inhibition of G1/S cell cycle transition and Akt/FOXO signaling⁸⁰. *RGS1* in 1q31.2 has been linked to multiple autoimmune diseases, including multiple sclerosis⁸¹, as well as poor prognosis in melanoma and diffuse large B cell lymphoma mediated by inactivation of Akt/ERK^{82,83}.

Other genes outside of the HLA region associated with viral infection response were detected for EBV EBNA in 3q25.1. The lead variant (rs67886110) is an eQTL for *MED12L* and *P2RY12* genes, which have been linked to neurodegenerative conditions^{84,85}. *P2RY12* and *P2RY13*, identified in TWAS, are purinergic receptor genes that regulate microglia homeostasis and have been implicated in Alzheimer's susceptibility via inflammatory and neurotrophic mechanisms⁸⁵.

442 Considering genetic variation within the HLA region, our results confirm its pivotal role at the interface of 443 host pathogen interactions and highlight the extensive sharing of HLA variants that mediate these 444 interactions across virus families and antigens. Genes in this region code for cell-surface proteins that 445 facilitate antigenic peptide presentation to immune cells that regulate responses to invading pathogens.

18

446 This region is critical for adaptive immune response but also has significant overlap with susceptibility 447 alleles for autoimmune diseases. We identified 40 independent SNPs/indels associated with EBV (EBNA, EA-D, VCA p18, and ZEBRA), VZV, and MCV antibody response that accounted for all significant HLA 448 449 associations for other phenotypes. Of the 14 conditionally independent, genome-wide significant classical 450 alleles identified for 10 antigens, 7 were associated with multiple phenotypes. The most commonly shared HLA alleles were DRB5*00:00, DRB1*04:04, an known rheumatoid arthritis risk allele⁸⁶, and DQB1*02:01, 451 associated with celiac disease risk⁸⁷. Copy number deletion represented by DRB5*00:00 may itself have a 452 functional role in altering response by the absence of these alleles. DRB5*00:00 also summarizes signals 453 454 from multiple HLA loci, including the extended DRB5*01:01-DRB1*15:01-DQB1*06:02-DQA1*01:02 455 haplotype that has been implicated in the etiology of multiple autoimmune diseases and EBV EBNA IgG levels. DRB1*15:01-DQB1*06:02-DQA1*01:02 is protective for type 1 diabetes⁸⁸, while DRB5*01:01-456 DRB15:01 confers the strongest risk for developing multiple sclerosis⁸¹. Amino acid residues in DRB1 at 457 458 positions 11, 13, 71, and 74 and in DQB1 codon 57 represent established susceptibility loci for rheumatoid arthritis⁸⁹, type 1 diabetes⁹⁰, and multiple sclerosis⁹¹ that exhibited strong associations with IgG levels for 459 EBV, HHV7, VZV, JCV, and MCV antigens, and in some cases harbored the top signal of all HLA variants. 460 Further research is needed to delineate shared genetic pathways that invoke autoimmunity and influence 461 462 viral response.

463 Despite the predominance of association in HLA class II, several notable associations in HLA class I were 464 detected. A*29:02 conferred reduced MCV seroreactivity and its sequence overlaps with amino acid residues in the A α 1 domain (Thr-9, Leu-62, Gln-63, Asn-77, and Met-97) that were also significantly 465 associated with decreased MCV antibody response. This is consistent with downregulation of MHC I as a 466 467 potential mechanism through which Merkel cell tumors evade immune surveillance⁹². The strongest residue-specific signal for EBV EA-D and VZV mapped to B-Asp-9, which is located in the peptide binding 468 groove and tags the B*08:01 allele, part of the HLA 8.1 ancestral haplotype. There is extensive evidence 469 linking HLA 8.1, and B*08:01 specifically, with autoimmune diseases⁹³ and certain cancers^{94,95}, which may 470 471 be attributed to its high cell-surface stability and increased probability of CD8+ T cell activation.

Comparison with other studies of host genetics and viral infection susceptibility shows that our results align 472 with previously reported findings^{7-9,96} (Supplementary Table 29). We replicated most associations from 473 two of the largest GWAS of humoral immune response in European ancestry subjects by Hammer et al.⁷ 474 (n=2363) and Scepanovic et al.⁸ (n=1000), including HLA SNPs, alleles, amino acids, and haplotypes linked 475 476 to EBV EBNA IgG, MCV IgG and serostatus, and JCV serostatus. We also replicated two HLA-DRB1 477 variants (rs477515, rs2854275) associated with EBV EBNA antibody levels in a Mexican American population⁹. GWAS of HPV16 L1 replicated a variant previously linked to HPV8 seropositivity (rs9357152, 478 $P=0.008)^6$. Some of our findings contrast with Tian et al ¹³, although we confirmed selected associations, 479 480 such as A*02:01 (shingles) with VZV (P=4.1×10⁻⁸) and rs2596465 (mononucleosis) with EBV EBNA $(P=3.3\times10^{-9})$ and EBV p18 $(P=1.0\times10^{-12})$. These differences may be partly accounted for by self-reported 481 482 disease status in Tian et al. which is likely to reflect symptom severity and may be an imprecise indicator of infection with certain viruses or the magnitude of antibody response to infection. 483

484 One of the most striking findings in SNP-based HLA analyses was the genome-wide significant association 485 between rs9273325, index VZV antibody response variant, and risk of schizophrenia. Previous 486 epidemiologic and serologic studies have linked infections to schizophrenia, although the underlying mechanisms remain to be elucidated⁹⁷. Viruses are plausible etiologic candidates for schizophrenia due to 487 their ability to invade the central nervous system and disrupt neurodevelopmental processes by targeting 488 specific neurons, as well as the potential for latent infection to negatively impact plasticity and neurogenesis 489 490 via pro-inflammatory and aberrant immune signaling^{97,98}. These observations are consistent with the established role the HLA region, including HLA-DQB1, in schizophrenia etiology^{99,100}, and is further 491 supported by previously reported associations for rs9273325 with blood cell traits⁵⁷ and immunoglobulin A 492 493 deficiency¹⁰¹, as well as its role as an eQTL for *HLA-DQB1* in CD4+ T₂h cells. Schizophrenia susceptibility alleles DRB1*03:0199, DQB1*02:01, and B*08:01 were also the top three alleles associated with VZV 494 495 antibody response in the unconditional analysis. Enhanced complement activity has been proposed as the mechanism mediating the synaptic loss and excessive pruning which is a hallmark of schizophrenia 496 pathophysiology¹⁰². Complement component 4 (C4) alleles were found to increase risk of schizophrenia 497 proportionally to their effect on increasing C4A expression in brain tissue¹⁰². Using gene expression models 498 in whole blood and the frontal cortex we demonstrated that increased C4A expression is negatively 499

20

associated with VZV antibody response. We also observed associations with *C4A* and *C4B* in EBV and HSV-1, but not other viruses. Taken together, these findings delineate a potential mechanism through which aberrant immune response to VZV infection, and potentially HSV-1 and EBV, may increase susceptibility to schizophrenia. However, cautious interpretation is warranted due to significant pleiotropy between HLA loci associated with viral infection and broad immune function.

505 Several limitations of this work should be noted. First, the UK Biobank is unrepresentative of the general UK population due to low participation resulting in healthy volunteer bias¹⁰³. However, since the observed 506 pattern of seroprevalence is consistent with previously published estimates¹⁵ we believe the impact of this 507 bias is likely to be minimal on genetic associations with serological phenotypes. Second, our analyses were 508 509 restricted to participants of European ancestry due to limited serology data for other ancestries, which limits 510 the generalizability of our findings to diverse populations. Third, we were unable to conduct formal statistical 511 replication of novel GWAS and TWAS signals in an independent sample due to the lack of such a population. Nevertheless, our successful replication of multiple previously reported variants and, combined 512 513 with the observation that newly discovered genes and variants are part of essential adaptive and innate 514 immunity pathways, support the credibility of our findings. Lastly, we also stress caution in the interpretation of GWAS results for non-ubiquitous pathogens, such as HBV, HCV, and HPV, due to a lack of information 515 516 on exposure, as well as low numbers of seropositive individuals.

517 Our study also has distinct advantages. The large sample size of the UK Biobank facilitated more powerful 518 genetic association analyses than previous studies, particularly in a population-based cohort unselected for 519 disease status. Our detailed HLA analysis shows independent effects of specific HLA alleles and pleiotropic 520 effects across multiple viruses. Analyses of genetic associations in external datasets further demonstrate 521 a connection between host genetic factors influencing immune response to infection and susceptibility to 522 cancers and neurological conditions.

The results of this work highlight widespread genetic pleiotropy between pathways involved in regulating humoral immune response to novel and common viruses, as well as complex diseases. The complex evolutionary relationship between viruses and humans is not dictated simply by infection and acute sickness, it is a complex nuanced architecture of initial challenge tempered with tolerance of viral latency

- 527 over time. Yet it is that architecture that is evolutionarily optimized to maximize fitness early in life, the result
- 528 of which may be increased risk for complex diseases later in life. Understanding this complex interplay
- 529 through both targeted association studies and functional investigations between host genetic factors and
- 530 immune response has implications for complex disease etiology and may facilitate the discovery of novel
- 531 therapeutics in a wide range of diseases.

532 DATA AVAILABILITY

- 533 The UK Biobank in an open access resource, available at https://www.ukbiobank.ac.uk/researchers/.
- 534 This research was conducted with approved access to UK Biobank data under application number
- 535 14105 (PI: Witte).

536 WEB RESOURCES

- 537 PLINK 2.0: https://www.cog-genomics.org/plink/2.0/
- 538 PLINK 1.07 conditional haplotype module: <u>https://zzz.bwh.harvard.edu/plink/whap.shtml</u>
- 539 R packages for pathway analysis: https://bioconductor.org/packages/release/bioc/html/ReactomePA.html
- 540 and https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html
- 541 Database of HLA allele frequencies and amino acid substitutions:
- 542 <u>http://www.allelefrequencies.net/hla9001a.asp?type_analysis=by_pops</u>
- 543

544 **ACKNOWLEDGEMENTS**

- 545 This research was supported by funding from the National Institutes of Health (US NCI R25T CA112355
- and R01 CA201358; PI: Witte). Maike Morrison was funded by the University of California San
- 547 Francisco's Amgen Scholars Program.

548

549 COMPETING INTERESTS

550 The authors declare no competing interests.

551 References

- 552 1. Aiewsakun, P. & Katzourakis, A. Marine origin of retroviruses in the early Palaeozoic Era. *Nat* 553 *Commun* **8**, 13954 (2017).
- 2. Wang, W. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA (2020).

Moore, P.S. & Chang, Y. Why do viruses cause cancer? Highlights of the first century of human
tumour virology. *Nat Rev Cancer* 10, 878-89 (2010).

- 4. Engdahl, E. *et al.* Increased Serological Response Against Human Herpesvirus 6A Is Associated
 With Risk for Multiple Sclerosis. *Front Immunol* **10**, 2715 (2019).
- 559 5. Readhead, B. *et al.* Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of 560 Molecular, Genetic, and Clinical Networks by Human Herpesvirus. *Neuron* **99**, 64-82 e7 (2018).
- 6. Chen, D. *et al.* Genome-wide association study of HPV seropositivity. *Hum Mol Genet* 20, 4714-23
 (2011).
- 7. Hammer, C. *et al.* Amino Acid Variation in HLA Class II Proteins Is a Major Determinant of Humoral
 Response to Common Viruses. *Am J Hum Genet* **97**, 738-43 (2015).
- 565 8. Scepanovic, P. *et al.* Human genetic variants and age are the strongest predictors of humoral 566 immune responses to common pathogens and vaccines. *Genome Med* **10**, 59 (2018).
- 9. Rubicz, R. *et al.* A genome-wide integrative genomic study localizes genetic factors influencing
 antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1). *PLoS Genet* 9, e1003147
 (2013).
- Liu, S. *et al.* Genomic Analyses from Non-invasive Prenatal Testing Reveal Genetic Associations,
 Patterns of Viral Infections, and Chinese Population History. *Cell* **175**, 347-359 e14 (2018).
- Besson, C. *et al.* Strong correlations of anti-viral capsid antigen antibody levels in first-degree
 relatives from families with Epstein-Barr virus-related lymphomas. *J Infect Dis* **199**, 1121-7 (2009).
- 574 12. Kenney, A.D. *et al.* Human Genetic Determinants of Viral Diseases. *Annu Rev Genet* **51**, 241-263
 575 (2017).
- Tian, C. *et al.* Genome-wide association and HLA region fine-mapping studies identify susceptibility
 loci for multiple common infections. *Nat Commun* 8, 599 (2017).
- 578 14. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562,
 579 203-209 (2018).
- Mentzer, A.J. *et al.* Identification of host-pathogen-disease relationships using a scalable Multiplex
 Serology platform in UK Biobank. *medRxiv*, 19004960 (2019).
- 582 16. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
 583 *Bioinformatics* 26, 2867-73 (2010).
- Waterboer, T. *et al.* Multiplex human papillomavirus serology based on in situ-purified glutathione
 s-transferase fusion proteins. *Clin Chem* **51**, 1845-53 (2005).
- 18. Waterboer, T., Sehr, P. & Pawlita, M. Suppression of non-specific binding in serological Luminex
 assays. *J Immunol Methods* **309**, 200-4 (2006).

- Kreimer, A.R. *et al.* Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to
 Oropharyngeal Cancer. *J Natl Cancer Inst* **109**(2017).
- 590 20. Peterson, R.A. & Cavanaugh, J.E. Ordered quantile normalization: a semiparametric 591 transformation built for the cross-validation era. *Journal of Applied Statistics*, 1-16 (2019).
- 592 21. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J. & Kircher, M. CADD: predicting the 593 deleteriousness of variants throughout the human genome. *Nucleic Acids Res* **47**, D886-D894 594 (2019).
- 595 22. Dong, S. & Boyle, A.P. Predicting functional variants in enhancer and promoter elements using 596 RegulomeDB. *Hum Mutat* **40**, 1292-1298 (2019).
- Schmiedel, B.J. *et al.* Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression.
 Cell 175, 1701-1715 e16 (2018).
- 599 24. Sun, B.B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73-79 (2018).
- Yao, C. *et al.* Genome-wide mapping of plasma protein QTLs identifies putatively causal genes
 and pathways for cardiovascular disease. *Nat Commun* 9, 3268 (2018).
- Rashkin, S.R. *et al.* Pan-Cancer Study Detects Novel Genetic Risk Variants and Shared Genetic
 Basis in Two Large Cohorts. *bioRxiv*, 635367 (2019).
- Lam, M. *et al.* Comparative genetic architectures of schizophrenia in East Asian and European
 populations. *Nat Genet* **51**, 1670-1678 (2019).
- Jun, G. *et al.* A novel Alzheimer disease locus located near the gene encoding tau protein. *Mol Psychiatry* 21, 108-17 (2016).
- Motyer, A. *et al.* Practical Use of Methods for Imputation of HLA Alleles from SNP Genotype Data.
 bioRxiv, 091009 (2016).
- 30. Jia, X. *et al.* Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS One* 8, e64683 (2013).
- Gonzalez-Galarza, F.F. *et al.* Allele frequency net database (AFND) 2020 update: gold-standard
 data classification, open access genotype data and new query tools. *Nucleic Acids Res* 48, D783D788 (2020).
- Barbeira, A.N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression
 variation inferred from GWAS summary statistics. *Nat Commun* 9, 1825 (2018).
- Barbeira, A.N. *et al.* Widespread dose-dependent effects of RNA expression and splicing on
 complex diseases and traits. *bioRxiv*, 814350 (2019).
- 34. Urbut, S.M., Wang, G., Carbonetto, P. & Stephens, M. Flexible statistical methods for estimating
 and testing effects in genomic studies with multiple conditions. *Nat Genet* **51**, 187-195 (2019).
- 35. Wen, X., Lee, Y., Luca, F. & Pique-Regi, R. Efficient Integrative Multi-SNP Association Analysis via
 Deterministic Approximation of Posteriors. *Am J Hum Genet* **98**, 1114-1129 (2016).
- 36. Lee, Y., Luca, F., Pique-Regi, R. & Wen, X. Bayesian Multi-SNP Genetic Association Analysis:
 624 Control of FDR and Use of Summary Statistics. *bioRxiv*, 316471 (2018).

- 37. Steiner, I., Kennedy, P.G. & Pachner, A.R. The neurotropic herpes viruses: herpes simplex and
 varicella-zoster. *Lancet Neurol* 6, 1015-28 (2007).
- Khalili, K., Del Valle, L., Otte, J., Weaver, M. & Gordon, J. Human neurotropic polyomavirus, JCV,
 and its role in carcinogenesis. *Oncogene* 22, 5181-91 (2003).
- Feng, H., Shuda, M., Chang, Y. & Moore, P.S. Clonal integration of a polyomavirus in human Merkel
 cell carcinoma. *Science* **319**, 1096-100 (2008).
- 40. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage,
 supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 47,
 D607-D613 (2019).
- 634 41. Shin, O.S. *et al.* LPLUNC1 modulates innate immune responses to Vibrio cholerae. *J Infect Dis*635 **204**, 1349-57 (2011).
- 42. Shafi, O. Inverse relationship between Alzheimer's disease and cancer, and other factors
 contributing to Alzheimer's disease: a systematic review. *BMC Neurol* **16**, 236 (2016).
- Gragert, L., Madbouly, A., Freeman, J. & Maiers, M. Six-locus high resolution HLA haplotype
 frequencies derived from mixed-resolution DNA typing for the entire US donor registry. *Hum Immunol* 74, 1313-20 (2013).
- 44. Degenhardt, F. *et al.* Construction and benchmarking of a multi-ethnic reference panel for the
 imputation of HLA class I and II alleles. *Hum Mol Genet* 28, 2078-2092 (2019).
- 643 45. Chen, Q., Sun, L. & Chen, Z.J. Regulation and function of the cGAS-STING pathway of cytosolic
 644 DNA sensing. *Nat Immunol* **17**, 1142-9 (2016).
- Kwon, J. & Bakhoum, S.F. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. *Cancer Discov* 10, 26-39 (2020).
- Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor
 that activates the type I interferon pathway. *Science* 339, 786-91 (2013).
- 48. Inoue, T. & Tsai, B. How viruses use the endoplasmic reticulum for entry, replication, and assembly. *Cold Spring Harb Perspect Biol* 5, a013250 (2013).
- 49. Woo, S.R. *et al.* STING-dependent cytosolic DNA sensing mediates innate immune recognition of
 immunogenic tumors. *Immunity* 41, 830-42 (2014).
- 50. Demaria, O. *et al.* STING activation of tumor endothelial cells initiates spontaneous and therapeutic
 antitumor immunity. *Proc Natl Acad Sci U S A* **112**, 15408-13 (2015).
- 655 51. Ohkuri, T. *et al.* STING contributes to antiglioma immunity via triggering type I IFN signals in the
 656 tumor microenvironment. *Cancer Immunol Res* 2, 1199-208 (2014).
- Fu, J. *et al.* STING agonist formulated cancer vaccines can cure established tumors resistant to
 PD-1 blockade. *Sci Transl Med* 7, 283ra52 (2015).
- 659 53. Corrales, L. *et al.* Direct Activation of STING in the Tumor Microenvironment Leads to Potent and
 660 Systemic Tumor Regression and Immunity. *Cell Rep* **11**, 1018-30 (2015).

- 661 54. Ohkuri, T., Ghosh, A., Kosaka, A., Sarkar, S.N. & Okada, H. Protective role of STING against
 662 gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. *Oncoimmunology* 4,
 663 e999523 (2015).
- 55. Ikeda, K. *et al.* Identification of ARIA regulating endothelial apoptosis and angiogenesis by
 modulating proteasomal degradation of cIAP-1 and cIAP-2. *Proc Natl Acad Sci U S A* **106**, 822732 (2009).
- 56. Verma, A. *et al.* Endothelial cell-specific chemotaxis receptor (ecscr) promotes angioblast migration
 during vasculogenesis and enhances VEGF receptor sensitivity. *Blood* **115**, 4614-22 (2010).
- 669 57. Astle, W.J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common
 670 Complex Disease. *Cell* **167**, 1415-1429 e19 (2016).
- 58. Assinger, A. Platelets and infection an emerging role of platelets in viral infection. *Front Immunol*57. 5, 649 (2014).
- Kelly, R.J., Rouquier, S., Giorgi, D., Lennon, G.G. & Lowe, J.B. Sequence and expression of a
 candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2).
 Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the nonsecretor phenotype. *J Biol Chem* 270, 4640-9 (1995).
- 677 60. Hazra, A. *et al.* Common variants of FUT2 are associated with plasma vitamin B12 levels. *Nat* 678 *Genet* **40**, 1160-2 (2008).
- 679 61. Carlsson, B. *et al.* The G428A nonsense mutation in FUT2 provides strong but not absolute 680 protection against symptomatic GII.4 Norovirus infection. *PLoS One* **4**, e5593 (2009).
- 681 62. Ruvoen-Clouet, N., Belliot, G. & Le Pendu, J. Noroviruses and histo-blood groups: the impact of
 682 common host genetic polymorphisms on virus transmission and evolution. *Rev Med Virol* 23, 355666 (2013).
- 684 63. Imbert-Marcille, B.M. *et al.* A FUT2 gene common polymorphism determines resistance to rotavirus
 685 A of the P[8] genotype. *J Infect Dis* **209**, 1227-30 (2014).
- 686 64. Ikehara, Y. *et al.* Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes)
 687 involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG
 688 antibody. *Cancer Epidemiol Biomarkers Prev* **10**, 971-7 (2001).
- 689 65. Blackwell, C.C. *et al.* Non-secretion of ABO antigens predisposing to infection by Neisseria 690 meningitidis and Streptococcus pneumoniae. *Lancet* **2**, 284-5 (1986).
- 691 66. de Lange, K.M. *et al.* Genome-wide association study implicates immune activation of multiple 692 integrin genes in inflammatory bowel disease. *Nat Genet* **49**, 256-261 (2017).
- 693 67. Ellinghaus, D. *et al.* Analysis of five chronic inflammatory diseases identifies 27 new associations 694 and highlights disease-specific patterns at shared loci. *Nat Genet* **48**, 510-8 (2016).
- 695 68. Hoffmann, T.J. *et al.* A large electronic-health-record-based genome-wide study of serum lipids.
 696 Nat Genet 50, 401-413 (2018).

697	69.	Tanaka, T. et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and								
698		homocysteine blood concentrations. Am J Hum Genet 84, 477-82 (2009).								
699	70.	Liu, M. et al. Association studies of up to 1.2 million individuals yield new insights into the genetic								

700 etiology of tobacco and alcohol use. Nat Genet 51, 237-244 (2019).

- 701 71. McKay, J.D. *et al.* Large-scale association analysis identifies new lung cancer susceptibility loci
 702 and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet* 49, 1126-1132
 703 (2017).
- 704 72. Batista, C.M. *et al.* Adult neurogenesis and glial oncogenesis: when the process fails. *Biomed Res* 705 *Int* **2014**, 438639 (2014).
- 706 73. Yamagishi, S. *et al.* Netrin-5 is highly expressed in neurogenic regions of the adult brain. *Front Cell* 707 *Neurosci* 9, 146 (2015).
- 708 74. Leong, Y.A. *et al.* CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. *Nat* 709 *Immunol* **17**, 1187-96 (2016).
- 710 75. Willis, T.G. *et al.* Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9)
 711 at chromosome 1q21. *Blood* 91, 1873-81 (1998).
- 712 76. Deka, J. *et al.* Bcl9/Bcl9I are critical for Wnt-mediated regulation of stem cell traits in colon 713 epithelium and adenocarcinomas. *Cancer Res* **70**, 6619-28 (2010).
- 714 77. Pilli, M. *et al.* TBK-1 promotes autophagy-mediated antimicrobial defense by controlling
 715 autophagosome maturation. *Immunity* **37**, 223-34 (2012).
- 716 78. Gordon, D.E. *et al.* A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
 717 *Nature* (2020).
- 718 79. Zhu, L. *et al.* TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression
 719 and tumourigenesis. *Nat Cell Biol* **21**, 1604-1614 (2019).
- Yang, J. *et al.* Thyrotroph embryonic factor is downregulated in bladder cancer and suppresses
 proliferation and tumorigenesis via the AKT/FOXOs signalling pathway. *Cell Prolif* **52**, e12560
 (2019).
- 81. International Multiple Sclerosis Genetics, C. *et al.* Genetic risk and a primary role for cell-mediated
 immune mechanisms in multiple sclerosis. *Nature* **476**, 214-9 (2011).
- 82. Sun, M.Y. *et al.* Critical role for nonGAP function of Galphas in RGS1mediated promotion of
 melanoma progression through AKT and ERK phosphorylation. *Oncol Rep* **39**, 2673-2680 (2018).
- RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). *Histopathology* **70**, 595-621 (2017).
 Carreras, J. *et al.* Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). *Histopathology* **70**, 595-621 (2017).
- 731 84. Mukherjee, S. *et al.* Genetic data and cognitively defined late-onset Alzheimer's disease
 732 subgroups. *Mol Psychiatry* (2018).

- Keren-Shaul, H. *et al.* A Unique Microglia Type Associated with Restricting Development of
 Alzheimer's Disease. *Cell* 169, 1276-1290 e17 (2017).
- Jawaheer, D. *et al.* Dissecting the genetic complexity of the association between human leukocyte
 antigens and rheumatoid arthritis. *Am J Hum Genet* **71**, 585-94 (2002).
- 737 87. Vader, W. *et al.* The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude
 738 and breadth of gluten-specific T cell responses. *Proc Natl Acad Sci U S A* **100**, 12390-5 (2003).
- 88. Erlich, H. *et al.* HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the
 type 1 diabetes genetics consortium families. *Diabetes* 57, 1084-92 (2008).
- Raychaudhuri, S. *et al.* Five amino acids in three HLA proteins explain most of the association
 between MHC and seropositive rheumatoid arthritis. *Nat Genet* 44, 291-6 (2012).
- Hu, X. *et al.* Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR
 molecules drive type 1 diabetes risk. *Nat Genet* 47, 898-905 (2015).
- Patsopoulos, N.A. *et al.* Fine-mapping the genetic association of the major histocompatibility
 complex in multiple sclerosis: HLA and non-HLA effects. *PLoS Genet* 9, e1003926 (2013).
- Paulson, K.G. *et al.* Downregulation of MHC-I expression is prevalent but reversible in Merkel cell
 carcinoma. *Cancer Immunol Res* 2, 1071-9 (2014).
- 749 93. Candore, G., Lio, D., Colonna Romano, G. & Caruso, C. Pathogenesis of autoimmune diseases
 750 associated with 8.1 ancestral haplotype: effect of multiple gene interactions. *Autoimmun Rev* 1, 29751 35 (2002).
- Ferreiro-Iglesias, A. *et al.* Fine mapping of MHC region in lung cancer highlights independent
 susceptibility loci by ethnicity. *Nat Commun* 9, 3927 (2018).
- Abdou, A.M. *et al.* Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis
 factor (TNF) G-308A, and risk of non-Hodgkin lymphoma. *Leukemia* 24, 1055-8 (2010).
- 96. Sundqvist, E. *et al.* JC polyomavirus infection is strongly controlled by human leucocyte antigen
 class II variants. *PLoS Pathog* **10**, e1004084 (2014).
- 758 97. Khandaker, G.M. *et al.* Inflammation and immunity in schizophrenia: implications for
 759 pathophysiology and treatment. *Lancet Psychiatry* 2, 258-270 (2015).
- 98. Dickerson, F. *et al.* Schizophrenia is Associated With an Aberrant Immune Response to EpsteinBarr Virus. *Schizophr Bull* 45, 1112-1119 (2019).
- 762 99. International Schizophrenia, C. *et al.* Common polygenic variation contributes to risk of
 763 schizophrenia and bipolar disorder. *Nature* 460, 748-52 (2009).
- Schizophrenia Working Group of the Psychiatric Genomics, C. Biological insights from 108
 schizophrenia-associated genetic loci. *Nature* 511, 421-7 (2014).
- 766101.Bronson, P.G. et al. Common variants at PVT1, ATG13-AMBRA1, AHI1 and CLEC16A are767associated with selective IgA deficiency. Nat Genet 48, 1425-1429 (2016).
- 768 102. Sekar, A. *et al.* Schizophrenia risk from complex variation of complement component 4. *Nature*769 530, 177-83 (2016).

- 103. Fry, A. et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
- Participants With Those of the General Population. *Am J Epidemiol* **186**, 1026-1034 (2017).
- 772

Antigen		Ν	Chr	Position	Variant	Alle Effect		EAF	Beta ²	(SE)	Ρ	Function	Nearest Gene
CMV	pp52	5000	6	32301427	rs115378818	С	Т	0.978	0.633	(0.095)	2.9×10 ⁻¹¹	intronic	TSBP1
EBV	EA-D	6806	6	32665840	rs34825357	Т	TC	0.409	-0.114	(0.017)	2.0×10 ⁻¹¹	intergenic	MTCO3P1
EBV	EBNA	7003	3	151114852	rs67886110*	G	Т	0.596	0.103	(0.017)	1.3×10 ⁻⁹	intronic	MED12L
			6	32451762	rs9269233	А	С	0.249	0.315	(0.019)	3.5×10 ⁻⁶¹	intergenic	HLA-DRB9
EBV	VCA p18	7492	6	31486158	6:31486158	GT	G	0.245	0.197	(0.018)	7.1×10 ⁻²⁷	intergenic	PPIAP9
EBV	ZEBRA	7197	6	32637772	rs9274728	А	G	0.718	-0.315	(0.018)	4.7×10 ⁻⁶⁷	intergenic	HLA-DQB1
HHV6	IE1A	6077	7	139985625	rs2429218	Т	С	0.615	0.106	(0.019)	1.4×10 ⁻⁸	downstream	RP5-1136G2.1
			6	32602665	rs139299944	С	СТ	0.655	0.114	(0.017)	1.5×10 ⁻¹¹	intronic	HLA-DQA1
HHV7	U14	7481	11	118767564	rs75438046	G	А	0.970	0.280	(0.049)	1.3×10 ⁻⁸	3'-UTR	CXCR5 / BCL9L
			17	45794706	rs1808192	А	G	0.331	-0.099	(0.017)	9.8×10 ⁻⁹	intergenic	TBKBP1
HSV1	1gG	5468	6	32627852	rs1130420	G	А	0.583	-0.122	(0.019)	2.5×10 ⁻¹⁰	3'-UTR	HLA-DQB1
пэті			10	91189187	rs11203123*	А	С	0.988	0.512	(0.093)	3.9×10 ⁻⁸	intergenic	SLC16A12
VZV	gE/lg ¹	7289	6	32623193	rs9273325	G	А	0.831	-0.232	(0.021)	8.2×10 ⁻²⁸	intergenic	HLA-DQB1
BKV	VP1	7523	19	49206462	rs681343	С	Т	0.491	-0.125	(0.016)	4.7×10 ⁻¹⁵	synonymous	FUT2
JCV	VP1	4471	6	32589842	rs9271525	G	А	0.163	-0.318	(0.031)	3.9×10 ⁻²⁴	intergenic	HLA-DQA1
MCV	VP1	5219	3	18238783	rs776170649	СТ	С	0.790	-0.134	(0.024)	1.7×10 ⁻⁸	intergenic	LOC339862
			5	138865423	rs7444313	G	А	0.263	0.169	(0.021)	2.4×10 ⁻¹⁵	intergenic	<i>TMEM173</i>
			6	32429277	rs9268847	А	G	0.750	-0.195	(0.022)	2.4×10 ⁻¹⁹	intronic	HLA-DRB9

Table 1: Lead genome-wide significant variants ($P < 5.0 \times 10^{-8}$) for continuous antibody response phenotypes for antigens with at least 20% seroprevalence.

¹ VZV antigens gE and gI were co-loaded onto the same Luminex bead set

² Regression coefficients were estimated per 1 standard deviation increase in normalized MFI value z-scores with adjustment for age at enrollment, sex, body mass index, socioeconomic status (Townsend deprivation index), the presence of any autoimmune conditions, genotyping array, serology assay date, quality control flag and the top 10 genetic ancestry principal components

* Multi-allelic variants: rs67886110 (G/T and G/C) and rs11203123 (A/C and A/AC)



Figure 1: Flow chart describing the main serological phenotypes and association analyses

Figure 2: Results from genome-wide and regional association analyses of continuous antibody response phenotypes (MFI z-scores) among individuals seropositive for human polyomaviruses BKV, JCV, and Merkel cell (MCV). The lower two panels depict the association signal and linkage disequilibrium (LD) structure in the HLA region for JCV and MCV.



Figure 3: Regional association plots for conditionally independent HLA genetic variants that were significantly ($P < 5.0 \times 10^{-8}$, solid black line) associated with each continuous antibody response phenotype. The suggestive significance threshold corresponds to $P < 1.0 \times 10^{-6}$ (dotted black line).



Figure 4: Conditionally independent classical HLA alleles significantly ($P_{cond} < 5.0 \times 10^{-8}$, solid line) associated with each continuous antibody response phenotype. Only classical alleles that surpassed the Bonferroni-corrected significance threshold ($P < 4.6 \times 10^{-5}$, dotted line) were included in conditional analyses.



Allele	Frequency	Beta	(SE)	Pcond
DRB5*00:00	0.845	-0.210	(0.021)	1.7×10 ⁻²²
DRB1*04:04	0.041	0.357	(0.040)	1.3×10 ⁻¹⁸

Allele	Frequency	Beta	(SE)	P_{cond}	
DQA1*01:01	0.141	0.215	(0.027)	1.1×10 ⁻¹⁵	
DRB1*04:04	0.041	-0.362	(0.054)	3.0×10 ⁻¹¹	
A*29:02	0.042	-0.350	(0.051)	1.0×10 ⁻¹¹	
DRB1*15:01	0.144	-0.203	(0.029)	3.7×10 ⁻¹²	

Figure 5: TWAS associations with continuous antigen response phenotypes. Two Manhattan plots depicting the transcriptome-wide associations for genes with a positive direction of effect (increased expression leads to higher antibody response) and genes with a negative direction of effect (increased expression is associated with a reduced antibody response).

